Redaktion

ObjectiveThis study aims to evaluate the clinical impacts of topical and/or oral administration of compounds rich in omega-3 fatty acids from various sources, such as oils and foods, on psoriatic lesions.DesignA systematic review was carried out.Data sourcesSearches were conducted in six databases (PubMed, Cochrane, VHL, Scopus, Embase, and Web of Science) using descriptors related to fatty acids and psoriasis.Study selectionInclusion criteria were studies published in the last 10 years (2013-2023) that involved patients with psoriasis and provided quantitative clinical outcome data, such as psoriasis severity scale.Data extractionTwo independent reviewers carried out the initial screening of the titles and abstracts identified in the search. The quality of studies was evaluated using the Newcastle-Ottawa Scale, the Risk of Bias in Randomized Studies of Interventions, and the Joanna Briggs Institute critical appraisal checklist.ResultsOut of 8570 articles identified, 9 met the inclusion criteria. The quality of randomized clinical trials and observational studies varied from low to high risk of bias, according to the respective parameters of each checklist.ConclusionsMost studies demonstrated that the topical and/or oral administration of omega-3 fatty acids from different sources significantly improved clinical parameters, as measured by severity scales and the Psoriasis Area and Severity Index (PASI).Weiterlesen

Background and objectivesPsoriasis is a chronic inflammatory skin disease, and noninvasive diagnostic tools are essential for accurate diagnosis and treatment monitoring. Multiphoton microscopy (MPM) enables real-time, noninvasive skin imaging with submicron resolution. This study evaluated the diagnostic accuracy of MPM in psoriasis and its potential application in therapeutic monitoring.Patients and methodsThis prospective observational study enrolled 34 patients with psoriasis. It comprised three parts: (1) analysis of imaging features of lesional and nonlesional skin using multiphoton microscopy (MPM; Transcend Vivoscope); (2) evaluation of the diagnostic performance of MPM parameters compared with reflectance confocal microscopy (RCM); and (3) prospective monitoring of 24 patients treated with Benvitimod (Tapinarof) cream for 8 weeks (T0/T1/T2).ResultsMPM detected psoriasis characteristics (including hyperkeratosis, parakeratosis, an absent stratum granulosum, enlarged nucleus diameter, and absent bright rimming) with comparable diagnostic efficiency to RCM (AUC = 0.838, p < 0.001 vs. 0.824, p < 0.001). Psoriatic lesions showed significant perinuclear fluorescence accumulation compared to healthy skin (p < 0.001). All imaging features improved significantly after 8 weeks of treatment (p < 0.001). PASI/TLS scores showed correlations with the epidermal thickness (r = 0.403/0.492, p < 0.001), nuclear diameter (r = 0.4/0.375, p < 0.001), and fluorescence intensity (r = -0.419/-0.492, p < 0.001).ConclusionsMPM is a novel and non-invasive imaging technique for psoriasis evaluation and treatment monitoring.Weiterlesen

Efficacious and well-tolerated systemic, oral treatments for psoriasis are needed. We report preclinical and phase 1c (NCT06808815) results for DC-806, a small molecule interleukin (IL)-17 inhibitor, for the treatment of mild-to-moderate psoriasis. Preclinical results demonstrated DC-806 targets IL-17AA and IL-17AF with secukinumab-like therapeutic efficacy. In the phase 1c trial, 32 patients consented to receive twice daily (BID) doses of placebo or DC-806 (200 mg or 800 mg) for 28 days. No serious adverse events (SAEs) or discontinuations due to treatment-related adverse events (TRAEs) occurred. In an exploratory analysis, adjusted mean percentage reductions from baseline in psoriasis area and severity indices (PASI) at Day 29 were 43.7%, 15.1%, and 13.3% for 800 mg BID, 200 mg BID, and placebo arms, respectively (800 mg BID vs placebo, P value = 0.0008). DC-806 was found to be well tolerated with an acceptable safety profile and preliminary signals of clinical efficacy in mild-to-moderate psoriasis. EudraCT Identifier: 2021-002888-21.Weiterlesen

This study examined relationships between Early Maladaptive Schemas (EMS), emotion regulation, coping styles, and psoriasis outcomes in Istanbul, Turkey. Participants included 100 psoriasis patients (ages 25-45) and 107 healthy controls. Data were analyzed using structural equation modeling. Psoriasis patients scored significantly higher on six schemas: Emotional Deprivation, Approval Seeking, Pessimism, Self-Sacrifice, Punitiveness, and Unrelenting Standards (Cohen's d = 0.42-0.89). They also demonstrated greater emotion regulation difficulties and reduced adaptive coping. Mediation analyses revealed that maladaptive emotion-focused coping fully mediated relationships between EMS and quality of life deterioration (β = .11, 95% CI (.04, .19]) and psoriasis severity (β = .08, 95% CI [.02, .15]). Pessimism and Punitiveness schemas, impulse control difficulties, and maladaptive emotion-focused coping predicted general psychological symptom severity (measured by validated scales) (R2 = .46). Findings suggest maladaptive emotion-focused coping as a key mechanism linking schemas to psoriasis outcomes, supporting integrated dermatological and psychological interventions.Weiterlesen

Psoriatic arthritis develops in up to one-third of individuals with psoriasis, typically following a prolonged subclinical phase. Diagnostic delays are common, often exceeding 2 years, and can result in irreversible joint damage. The growing recognition of this latent period has fuelled interest in earlier identification and interception. However, efforts are hampered by inconsistent definitions of early or subclinical psoriatic arthritis, insufficient prognostic tools, and an absence of consensus on the outcome for interception studies. This Review synthesises a rapidly evolving field, offering a framework organised around four crucial questions: first, what defines progression from psoriasis to psoriatic arthritis? Second, who is most at risk of transition? Third, how can progression be reliably measured using imaging, molecular biomarkers, or digital health technologies? Fourth, when should preventive intervention be considered? We critically examine new conceptual models, the limitations of existing classification criteria, advances in imaging and biomarker research, and the promise of digital phenotyping. Addressing the current challenges in definitions, risk stratification, measurement, and trial design is essential for the development of biologically grounded, ethically robust interception strategies.Weiterlesen

Psoriasis and psoriatic arthritis (PsA) occasionally coexist with antinuclear antibody (ANA) positivity, cutaneous lupus erythematosus (CLE), or systemic lupus erythematosus (SLE), creating one of the most challenging therapeutic overlap scenarios in immunodermatology. Divergent immune pathways-IL-23/Th17-driven psoriatic inflammation versus type I interferon-mediated autoimmunity-generate unique vulnerabilities when systemic treatments are used. To synthesize treatment outcomes, lupus-related safety signals, and mechanistic insights across systemic therapies in patients with psoriasis or PsA who also exhibit ANA positivity, CLE, or SLE. A systematic review following PRISMA 2020 guidelines was conducted across PubMed/MEDLINE, Embase, the Cochrane Library, Scopus, and ClinicalTrials.gov from database inception through 31 October 2025. Thirty-three eligible reports (29 unique clinical studies; 1429 patients) were included and organized into six prespecified overlap subgroups. Mechanistic and translational studies-including ustekinumab and deucravacitinib SLE trial data and reports of IL-17 inhibitor-associated CLE-were reviewed separately to provide contextual interpretation. IL-23 inhibitors were consistently associated with a favorable cross-disease safety profile, with no clear signal for CLE worsening, SLE flares, or drug-induced autoimmunity. IL-17 inhibitors maintained strong psoriatic efficacy but were associated with an increased frequency of de novo or exacerbated CLE. TNF-α inhibitors showed the strongest association with ANA seroconversion, anti-dsDNA induction, drug-induced lupus, and lupus flares. Ustekinumab demonstrated a stable safety profile across lupus-spectrum disease despite variable efficacy in formal SLE trials. TYK2 inhibition provided dual modulation of IL-23 and type I interferon pathways and showed emerging utility in psoriasis or PsA coexisting with CLE or SLE. Apremilast, methotrexate, and mycophenolate mofetil remained reliable non-biologic systemic options. Phototherapy was associated with potential risk in ANA-positive or lupus-susceptible populations and therefore requires careful consideration. Interpretation is limited by the predominantly observational nature and heterogeneity of the available evidence. IL-23 inhibition and TYK2 inhibition appear to offer a balanced profile of efficacy and lupus-related safety in psoriatic disease complicated by lupus-spectrum autoimmunity. IL-17 inhibitors and TNF-α inhibitors may be associated with higher risk in CLE- or SLE-prone patients and therefore warrant particular caution. Personalized treatment strategies should integrate the relative dominance of psoriatic versus lupus disease, ANA/ENA profile, CLE subtype, and underlying mechanistic considerations. Prospective, biomarker-driven studies are needed to guide therapy in this increasingly recognized overlap population (PROSPERO registration: CRD420251241279).Weiterlesen

Objective and designThis prospective multicenter cohort study was conducted to identify and compare clinical factors associated with the effectiveness of commonly used biologics in Chinese patients with moderate-to-severe psoriasis.SubjectsPatients from the SPEECH registry initiating treatment with ixekizumab, secukinumab, guselkumab, or ustekinumab were included.TreatmentGuideline-recommended dosing; 3-month follow-up.MethodsThe primary endpoint was PASI90 response at 3 months. Multivariable logistic regression estimated adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for clinical predictors of treatment response.ResultsA total of 717 patients were included in the analysis. In guselkumab-treated patients, obesity (aOR 0.22, 95% CI 0.06-0.78) and prior biologic exposure (aOR 0.22, 95% CI 0.06-0.75) were independently associated with reduced PASI90 response. Psoriatic arthritis predicted poorer response to ustekinumab (aOR 0.16, 95% CI 0.03-0.78). For secukinumab, male sex reduced the likelihood of PASI90 (aOR 0.47, 95% CI 0.23-0.96), whereas family history of psoriasis improved outcomes (aOR 2.20, 95% CI 1.10-4.42). In ixekizumab-treated patients, obesity (aOR 0.38, 95% CI 0.18-0.80) was a negative predictor, while family history (aOR 2.79, 95% CI 1.22-6.38) enhanced treatment response.ConclusionsPredictors of biologic effectiveness differ by agent, supporting personalized treatment based on patient characteristics.Weiterlesen

No abstract supplied.Weiterlesen

Originaltitel: Exploring clusters based on ultrasound-detected inflammation in patients with psoriatic arthritis: a post-hoc analysis from the ULTIMATE trial - BMC Musculoskeletal Disorders Link zur Quelle

Ich kann leider das spezifische JLE-Artikel nicht in den verfügbaren Suchergebnissen finden. Die Suchergebnisse enthalten andere hochwertige Quellen zu generalisierten pustulösen Psoriasis (GPP), aber nicht den exakten Artikel von JLE mit dem Fokus auf Mortalität, Prävalenz, Komorbiditäten und Schübe. Um den Artikel für Sie zusammenzufassen, benötige ich entweder: - Den vollständigen Text oder die Zusammenfassung des JLE-Artikels - Oder Zugriff auf die spezifische URL mit dem Artikel-Inhalt Falls Sie mir den Inhalt des Artikels zur Verfügung stellen, kann ich Ihnen sehr gerne eine verständliche Zusammenfassung im gewünschten Stil schreiben – locker, aber korrekt, und verständlich für Zehntklässler. Das wäre perfekt für ein Newsportal für Menschen mit Psoriasis oder Psoriasis arthritis. Originaltitel: JLE - European Journal of Dermatology - Mortality, prevalence, comorbidity, and flare patterns in generalised pustular psoriasis: a comprehensive literature review Link zur Quelle

# Neue Technologie zur Psoriasis-Diagnose Forscher haben eine neue Methode entwickelt, um Psoriasis früher und genauer zu erkennen[1]. Sie heißt Multiphoton-Mikroskopie und schaut sich die Haut von innen an, ohne dass man sie verletzten muss. Das Besondere daran ist, dass die Methode sehr genau arbeitet[1]. Sie zeigt nicht nur die oberflächliche Hautveränderung, sondern auch die winzigen Blutgefäße und tieferen Hautschichten. Bei Psoriasis-Patienten sind diese Gefäße deutlich dicker als bei gesunden Menschen – etwa doppelt so groß[1]. Das hilft nicht nur bei der Diagnose. Die Technologie kann auch kontrollieren, ob eine Behandlung funktioniert[2]. Man sieht direkt, ob die Blutgefäße wieder kleiner werden und die Entzündung nachlässt. Bisher musste man dafür eine Hautprobe nehmen – das ist schmerzhaft und hinterlässt eine Narbe[1]. Experten sehen darin großes Potenzial. Mit dieser Methode können Ärzte ihre Therapie besser abstimmen und Patienten schneller sehen, ob die Behandlung anschlägt[2]. Originaltitel: In vivo multiphoton microscopy of psoriasis: A new diagnosis and therapeutic monitoring technique Link zur Quelle

Acne tarda is defined in the literature as adult acne, which according to most authors occurs in women aged 25 and older. However, the definitions and age groups vary depending on the study. Current guidelines rarely address adult acne. In this review, current studies and the literature on acne tarda are analyzed and evaluated by German experts. Recommendations regarding classification, clinical features, differentiation, and treatment of acne tarda were summarized in a consensus based on the discussion. The recommendations also include the treatment of post-inflammatory erythema/hyperpigmentation and acne scars, as well as the accompanying skin care. The goal is to improve the treatment of patients with acne tarda.Weiterlesen

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

Background and objectivesPalmoplantar pustulosis (PPP) is a chronic and refractory inflammatory skin disorder with unclear pathogenesis.Patients and methodsTen PPP patients treated with upadacitinib were monitored to assess efficacy and safety. Immunofluorescence and immunohistochemistry were employed to evaluate Th1, Th2, and Th17 cell expressions, along with their associated cytokines in lesions on palms or soles from 16 PPP patients, 10 chronic eczema (CE) patients, 10 psoriasis vulgaris (PV) patients, and 7 healthy controls (HC).ResultsIn PPP patients receiving upadacitinib, the shortest time to achieve PPPASI75 and PPPASI90 was 4 weeks and 8 weeks, respectively. The rates of patients achieving PPPASI90 at week 16, week 24, and week 52 was 70 %, 100 %, and100 %, respectively. Th1 cells and IFN-γ levels in PPP were comparable to CE and PV, and higher than HC. Th2 cells, IL-4, and IL-13 levels in PPP were similar to CE, and greater than HC and PV. Th17 cells, IL-17, and IL-36γ levels in PPP were comparable to PV, and more abundant than HC and CE.ConclusionsUpadacitinib is a safe and effective option for PPP patients, which may be attributed to the complex Th1, Th2, and Th17 inflammatory responses associated with PPP.Weiterlesen

Background and objectivesPeople with skin disease often experience stigmatization in health and body care settings, significantly impacting their quality of life. This parallel-group randomized controlled trial evaluated a face-to-face group seminar aimed at reducing stigma towards people with skin disease among health and body care professionals (HBCPs).Patients and methodsCosmetologists, hairdressers, nurses, and physical therapists were randomized into an intervention (IG; n = 64) or control group (CG; n = 65). The IG received a seminar consisting of self-awareness exercises, education and a patient encounter; the CG followed a seminar on "health at work". Stereotype agreement, disease-related misconceptions, desire for social distance, and behavioral intentions were assessed at baseline (t0), post-intervention (t1), and 3 months follow-up (t2).ResultsThe intervention group showed significant reductions over time in disease-related misconceptions (t0-t1: 0.398, p < 0.001; t0-t2: 0.225, p < 0.001; ηp2 = 0.12) and in stereotype endorsement (t0-t1: 0.392, p < 0.001; t0-t2: 0.299, p = 0.002; ηp2 = 0.12). In both groups, the desire for social distance decreased immediately after the seminar (t0-t1Intervention: 0.186, p < 0.001; t0-t1Control: 0.135, p = 0.012) but returned to baseline at follow-up (t0-t2Intervention: 0.097, p = 0.35; t0-t2Control: 0.016, p = 1.00).ConclusionsThe seminar improved skin disease-related stigmatizing beliefs and attitudes of HBCPs. Its integration into vocational training curricula or delivery in workshops to increase knowledge about skin diseases and to reduce prejudices in various professional groups is promising.Weiterlesen

This first part of the updated German S3 guideline on the treatment of psoriasis vulgaris covers the sections on treatment recommendations, treatment goals, and monitoring of therapies. The recommendations are based on the current Cochrane network meta-analysis, the results of which are also summarized. When selecting systemic therapies for psoriasis vulgaris, the guideline emphasizes consideration of efficacy, safety, comorbidities, and individual patient factors. The decision framework is presented in the treatment options overview, and in this updated version, the possibility of first-line therapy with biologics or novel targeted small molecules is more prominently highlighted. Standardized instruments for assessing disease severity, as well as patient-centered treatment goals, are underscored. A Psoriasis Area and Severity Index (PASI) 75 response is defined as the minimum therapeutic target, while PASI 90 or an absolute PASI <2 are considered desirable goals. Since the last version, two newly approved agents, bimekizumab and deucravacitinib, have been incorporated, accompanied by specific usage recommendations. Among the established therapies, guidance on methotrexate has been extensively revised, particularly regarding administration, dosing, and monitoring. This guideline aims to provide clinicians with an evidence-based framework for therapy selection and monitoring, while strengthening shared decision-making with patients.Weiterlesen

No abstract supplied.Weiterlesen

Psoriasis is a chronic inflammatory skin disease, and noninvasive diagnostic tools are essential for accurate diagnosis and treatment monitoring. Multiphoton microscopy (MPM) enables real-time, noninvasive skin imaging with submicron resolution. This study evaluated the diagnostic accuracy of MPM in psoriasis and its potential application in therapeutic monitoring. This prospective observational study enrolled 34 patients with psoriasis. It comprised three parts: (1) analysis of imaging features of lesional and nonlesional skin using multiphoton microscopy (MPM; Transcend Vivoscope); (2) evaluation of the diagnostic performance of MPM parameters compared with reflectance confocal microscopy (RCM); and (3) prospective monitoring of 24 patients treated with Benvitimod (Tapinarof) cream for 8 weeks (T0/T1/T2). MPM detected psoriasis characteristics (including hyperkeratosis, parakeratosis, an absent stratum granulosum, enlarged nucleus diameter, and absent bright rimming) with comparable diagnostic efficiency to RCM (AUC = 0.838, p < 0.001 vs. 0.824, p < 0.001). Psoriatic lesions showed significant perinuclear fluorescence accumulation compared to healthy skin (p < 0.001). All imaging features improved significantly after 8 weeks of treatment (p < 0.001). PASI/TLS scores showed correlations with the epidermal thickness (r = 0.403/0.492, p < 0.001), nuclear diameter (r = 0.4/0.375, p < 0.001), and fluorescence intensity (r = -0.419/-0.492, p < 0.001). MPM is a novel and non-invasive imaging technique for psoriasis evaluation and treatment monitoring.Weiterlesen

BackgroundPsoriasis is a systemic inflammatory disease associated with cardiopulmonary comorbidities. Nail psoriasis, quantified by the Nail Psoriasis Severity Index (NAPSI), is a marker of severe disease. While pulmonary arterial hypertension (PAH) is reported more frequently in psoriasis, the specific correlation between nail psoriasis severity and PAH remains underexplored.ObjectiveTo investigate the correlation between NAPSI scores and the presence or severity of PAH in patients with psoriasis.MethodsA prospective, cross-sectional study was conducted at a tertiary care centre involving 100 patients with chronic plaque psoriasis (50 with and 50 without nail psoriasis). All participants underwent dermatological evaluation [Psoriasis Area and Severity Index (PASI) and NAPSI scoring], transthoracic echocardiography to estimate pulmonary artery systolic pressure (PASP), and measurement of inflammatory markers [C-reactive protein (CRP), IL-17, TNF-α]. PAH was defined as PASP > 35 mmHg. Statistical analyses included correlation tests, comparative analyses, and multivariate logistic regression.ResultsPAH was identified in 29% (n = 29) of patients, with a significantly higher prevalence in the nail psoriasis group (40% vs 18%, P = .01). Patients with PAH had higher mean NAPSI scores than those without (29.5 ± 13.4 vs 18.2 ± 10.6, P = .001). A moderate positive correlation was found between NAPSI scores and PASP (r = 0.44, P < .001). PASI scores and CRP levels were also significantly elevated in patients with PAH and correlated with PASP (r = 0.38, P = .001 and r = 0.41, P < .001, respectively).Multivariate analysis confirmed NAPSI score as an independent predictor of PAH [odds ratio (OR): 1.07/unit increase, 95% CI: 1.03-1.11, P = .002], after adjusting for confounders including PASI score and comorbidities. PASI (OR: 1.05, P = .01) and CRP (OR: 1.13, P = .008) were also independent predictors. Nail matrix involvement was more strongly associated with PAH than nail bed involvement (P = .03). Inflammatory markers (CRP, IL-17, TNF-α) were significantly elevated in patients with PAH.ConclusionNAPSI scores, PASI scores, and CRP levels are all significantly correlated with and independently predict PAH in patients with psoriasis. Assessment of nail psoriasis severity may serve as a valuable, noninvasive clinical tool to identify psoriasis patients at increased risk of pulmonary vascular complications, warranting further cardiological evaluation.Weiterlesen

IntroductionThe German national psoriasis registry PsoBest collects long-term data on the effectiveness, safety, and tolerability of systemic treatments for psoriatic disease. Here, we describe patient characteristics and the safety and effectiveness of apremilast for the treatment of psoriatic disease in Germany based on data from PsoBest.MethodsThis was a descriptive analysis of observational data collected from PsoBest using cross-sectional (baseline characteristics) and longitudinal (outcomes, safety) designs. PsoBest recruits patients with moderate to severe plaque psoriasis or psoriatic arthritis who initiate a new systemic psoriasis treatment. Adverse events (AEs) and sociodemographic descriptors were reported for patients exposed to apremilast during the study period (safety cohort). Clinical and patient-reported outcomes were collected 3, 6, and 12 months after the initiation of apremilast monotherapy (outcomes cohort).ResultsFrom January 15, 2015 to June 30, 2020, 595 registry patients were exposed to apremilast; 417 were treated with apremilast monotherapy. Patients taking apremilast had a higher mean age and higher proportions of comorbidities such as cardiovascular or metabolic disease compared with those taking other nonbiologic systemic or biologic drugs. The most common nonserious AEs were drug ineffectiveness (14.1%), diarrhea (9.4%), nausea (7.1%), and headache (6.1%). The highest incidence rates of nonserious and serious AEs of special interest were for infections and infestations per system organ class (8.03/100 patient-years) and malignant or unspecified tumors (2.50/100 patient-years), respectively. Improvements in Dermatology Life Quality Index, patient-defined treatment benefits (Patient Benefit Index), body surface area, and Psoriasis Area and Severity Index were observed after 3, 6, and 12 months of apremilast treatment.ConclusionsPatients in routine care treated with apremilast in the German PsoBest registry experienced treatment benefits and improved skin, psoriasis severity, and quality of life. Safety was consistent with the established safety profile. Apremilast is safe and effective for treating moderate to severe psoriatic disease.Weiterlesen

IntroductionPsoriasis is a chronic inflammatory disease associated with multiple systemic comorbidities and reduced quality of life. Risankizumab, an interleukin (IL)-23 inhibitor, has demonstrated efficacy in achieving rapid and sustained skin clearance in moderate-to-severe psoriasis. However, its impact on chronic subclinical inflammation is less understood. Conventional clinical assessments like Psoriasis Area and Severity Index (PASI), Investigator's Global Assessment (IGA), and Body Surface Area (BSA) focus on evaluating visible symptoms and are limited in capturing underlying disease activity. Optical coherence tomography (OCT), a non-invasive imaging modality, offers real-time assessment of structural and vascular changes, providing valuable insights beyond the skin surface.MethodsThis sub-analysis of a prospective, single-center exploratory study included 22 patients with moderate-to-severe psoriasis treated with risankizumab. Clinical assessments (PASI, IGA, BSA) were conducted at baseline and weeks 2, 4, 16, 28, 40, and 52. OCT imaging performed at baseline and weeks 4, 16, and 52 evaluated epidermal thickness and vascular parameters (e.g., vessel density and diameter) in lesional and perilesional skin.ResultsBy week 16, mean (95% confidence interval [CI]) PASI score decreased from 16.3 (11.6-21.1) at baseline to 3.5 (1.8-5.2), and BSA involvement from 24.7% (16.1-33.3) to 5.2% (1.9-8.4) (both p < 0.001). By week 52, 86.7%, 73.3%, and 40.0% of patients achieved PASI 75, 90, and 100, respectively, and 93.3% achieved IGA 0/1. OCT showed lesional reductions in epidermal thickness (- 37.4%), vessel density (- 26.6% Δ area under the curve [AUC]), and vessel diameter (- 59.5% ΔAUC) over the 52-week period. Notably, vascular changes also occurred in uninvolved perilesional skin.ConclusionRisankizumab improved both clinical and OCT parameters over 52 weeks, emphasizing the importance of long-term therapy with benefits extending beyond visible improvement. OCT emerged as a valuable tool for assessing deep (vascular) treatment response, thereby supporting a more comprehensive understanding of therapeutic outcomes in psoriasis.Weiterlesen

Dual biologic therapy is not often used in psoriasis and psoriatic arthritis due to cost and safety concerns, with limited literature supporting its use. We present a case of a 31-year-old man with severe plaque psoriasis and erosive psoriatic arthritis, refractory to multiple therapies. While guselkumab improved skin symptoms, joint inflammation persisted. Given the patient's reluctance to discontinue guselkumab and his poor response to prior therapies, bimekizumab was added. This combination led to near-complete skin clearance and significant joint improvement within 3 months, with sustained benefits and no adverse effects at 17 months. This case illustrates how targeting multiple points in the interleukin-23/interleukin-17 pathway can improve outcomes in patients unresponsive to monotherapy. Dual biologic therapy may be a viable option for select patients with complex disease, though further research is needed to evaluate its long-term safety and efficacy.Weiterlesen

No abstract supplied.Weiterlesen

Abstract Atopic dermatitis and psoriasis are two dermatological diseases that affect the mental health of patients. The purpose of this research is to investigate the comparison of the psychometric characteristics of two groups of patients with psoriasis and atopic dermatitis respectively focusing on depression, personality, hostility and psychosomatic burden. Τhe sample was consisted by 100 patients with psoriasis and 40 patients with atopic dermatitis, respectively. Specific questionnaires were given for the psychometric evaluation of patients with atopic dermatitis and psoriasis. The Beck's Depression Inventory (BDI), the Eysenck Personality Questionnaire (EPQ) the Brief Symptom Inventory SCL-90 scale, and the HDHQ questionnaire (Psychometric Hostility and Direction of Hostility Questionnaire). Patients with atopic dermatitis have statistically significantly higher scores on the scale of somatization and paranoid ideation, while patients with psoriasis have statistically significantly higher scores on the scale of depression. On the personality scales, patients with atopic dermatitis have on average statistically significantly higher scores on the psychoticism scale and lower scores on the lying scale than the psoriatic patients. Patients with atopic dermatitis present statistically significantly higher scores on the scale of paranoid hostility than patients with psoriasis. Patients receiving medication as well as the interaction of disease group with receiving medication are statistically significantly related to the psychopathology index. Patients' scores on the psychotic scale of the EPQ are statistically significantly related to the duration of the illness and the patient group, gender and medication intake. The psychosocial effects of psoriasis and atopic dermatitis on patients' mental health are demonstrated in the present study based on patient scores on psychometric scales and psychopathology index. Weiterlesen